


## B-Raf IN 2

<b>Cat. No.:</b>	HY-145120
<b>CAS No.:</b>	2649372-20-1
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>17</sub> F <sub>2</sub> N <sub>5</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	461.44
<b>Target:</b>	Raf
<b>Pathway:</b>	MAPK/ERK Pathway
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (216.71 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b> \ <b>Concentration</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>1 mM</b>		2.1671 mL	10.8356 mL	21.6713 mL
		<b>5 mM</b>		0.4334 mL	2.1671 mL	4.3343 mL
		<b>10 mM</b>		0.2167 mL	1.0836 mL	2.1671 mL
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	BRaf <sup>V600E</sup>
<b>In Vitro</b>	B-Raf IN 2 shows considerably less paradoxical activation of the MAPK signaling pathway while retaining high potency <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Dolente C, et, al. New methylquinazolinone derivatives. WO2021116055A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA